Can we really beat cervical cancer?

Garland, Suzanne M

doi:10.5694/j.1326-5377.2003.tb05396.x

Topics

Women's health

Neoplasms

Sexual health

Vaccination has the potential to reduce the global burden of disease from genital HPV infection

Department of Microbiology and Infectious Diseases, Royal Women's Hospital, Carlton, VIC.

Correspondence:

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. Lyon: IARC Press, 2001. Available (in part) at: http://www-dep.iarc.fr/globocan/globocan.html (accessed May 2003).
2. International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risks to humans. Vol 64. Human papillomaviruses. Lyon: IARC, 1995.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
4. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
5. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer [review]. J Clin Pathol 2002; 55: 244-265.
6. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high-risk human papillomavirus as indicator of high-grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 572-576.
7. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46-52.
8. Digene Corporation press release. Digene high-risk HPV DNA test approved by the FDA for adjunctive screening in women age 30 and older. Gaithersburg, Md, USA, 1 April 2003. Available at: http: //www.digene.com/corporate01/press_releases/prelease_frame.html (accessed May 2003).
9. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
10. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257.
11. Bill and Melinda Gates Foundation press release. Alliance for Cervical Cancer Prevention receives $50 million gift from Bill and Melinda Gates. Seattle, Wash, USA, 22 Sept 1999. Available at: http://www.gatesfoundation.org/GlobalHealth/ReproductiveChildHealth/Announcements/Announce-98.htm (accessed May 2003).
12. Steller MA. Update on human papillomavirus vaccines for cervical cancer. Curr Opin Investig Drugs 2002; 3: 37-47.

Online responses are no longer available. Please refer to our instructions for authors page for more information.